menu
    • menu
    [{"orgOrder":0,"company":"Hisamitsu Pharmaceutical Co., Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Terbinafine Hydrochloride","moa":"SQLE||Squalene monooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hisamitsu Pharmaceutical Co., Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Hisamitsu Pharmaceutical Co., Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hisamitsu Pharmaceutical Co., Inc. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Hisamitsu Pharmaceutical Co., Inc.

    Menu

    Hisamitsu Pharmaceutical Co., Inc.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hisamitsu Pharmaceutical Co., Inc.

                            Japan arrow
                            BioFit
                            Not Confirmed

                            Hisamitsu Pharmaceutical Co., Inc.

                            Japan arrow
                            BioFit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terbinafine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail

                            Details : HTU-520 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Onychomycosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2011

                            Lead Product(s) : Terbinafine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth